<< Back to News

System Formulary Update
Baloxavir and Neuraminidase Inhibitors

Situation
The baloxavir and neuraminidase inhibitor class review and formulary standardization was approved by System Pharmacy and Therapeutics Committee in November 2019.

Background
The following medications were reviewed: oseltamivir, peramivir, zanamivir, and baloxavir

Assessment/Recommendation
Changes Effective: Tuesday, October 13, 2020

System P&T voted to include the following products on the UNC Health Medication Formulary: 

• Oseltamivir capsule: 30 mg, 75 mg
• Oseltamivir oral suspension: 6 mg/mL
• Peramivir IV solution: 200 mg/20 mL

Note: Stock of these products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary: 

• Oseltamivir capsule: 45 mg
• Oseltamivir oral suspension: 15 mg/mL
• Zanamivir dry powder for inhalation: 5 mg/actuation